Robert A. Bradway - 04 Mar 2026 Form 4 Insider Report for AMGEN INC (AMGN)

Role: Chairman, CEO and President, Director
Signature: /s/ Robert A. Bradway
Issuer symbol: AMGN
Transactions as of: 04 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2026, 19:32:13 UTC
Previous filing: 05 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bradway Robert A	Chairman, CEO and President, Director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS	/s/ Robert A. Bradway	05 Mar 2026	0001396482

Transactions Table

Type	Sym	Class	Transaction	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMGN	Common Stock	Options Exercise	+119,782	+26%	$156.35^*	576,928	04 Mar 2026	Direct	F1
transaction	AMGN	Common Stock	Tax liability	-84,285	-15%	$379.27^*	492,643	04 Mar 2026	Direct	F2
holding	AMGN	Common Stock					90,000	04 Mar 2026	By GRAT
holding	AMGN	Common Stock					90,000	04 Mar 2026	By Spousal GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMGN	Nqso (Right to Buy)	Options Exercise		-119,782	-100%	$0.000000^*	0	04 Mar 2026	Common Stock	119,782	$156.35	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Non-market exercise of a total of 119,872 stock options expiring May 3, 2026 wherein 84,285 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.
F2	These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Content

Non-market exercise of a total of 119,872 stock options expiring May 3, 2026 wherein 84,285 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.

These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.